Showing 3421-3430 of 5773 results for "".
- C. Light Receives FDA Clearance for Retinal Eye Movement Monitor, Retitrackhttps://modernod.com/news/c-light-receives-fda-clearance-for-retinal-eye-movement-monitor-retitrack/2481615/C. Light Technologies announced it has received 510(k) clearence from the FDA for the Retitrack, which is designed to provide new understanding and insight into oculomotor function via the retina, providing concrete and objective metrics to medical professionals. The
- New Museum of the Eye Exhibit Explores the Eye as a Cultural Symbol, From Ancient to Modern Timeshttps://modernod.com/news/new-museum-of-the-eye-exhibit-explores-the-eye-as-a-cultural-symbol-from-ancient-to-modern-times/2481612/Truhlsen-Marmor Museum of the Eye, the world’s only free, public museum dedicated to the science of sight, announced the opening of "Decoding the Eye: Signs and Symbols," a new exhibit exploring how the eye appears as a symbol throughout time. The exhibit will run from May 2023 to
- FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)https://modernod.com/news/fda-accepts-application-for-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo/2481608/Genentech announced that the FDA has accepted the company’s supplemental biologics license application (sBLA) for Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The sBLA is based on results from the phase 3 BALATON and COMINO st
- New Acuvue Campaign Encourages Gen Z to Take a Social Media Breakhttps://modernod.com/news/new-acuvue-campaign-encourages-gen-z-to-take-a-social-media-break/2481606/The Acuvue brand announced the "Where Vision Meets Sight" social media campaign (#MyVisionMySight) that aims to encourage Gen Z to take social media breaks—to not only give their eyes a rest, but also recognize the impact screen time is having in their lives, according t
- Trefoil’s TTHX1114 Improves Rate of Visual Recovery After Descemet Stripping Only (DSO) in Phase 2 STORM Datahttps://modernod.com/news/trefoils-investigational-candidate-tthx1114-improves-rate-of-visual-recovery-after-descemet-stripping-only-dso-in-phase-2-storm-data-presented-at-ascrs/2481605/Trefoil Therapeutics announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the ph
- Salvat Laboratories Presents Phase 3 Clinical Trials Results of Clobetasol Nanoemulsion for Treating Inflammation and Pain After Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-presents-phase-3-clinical-trials-results-of-clobetasol-nanoemulsion-for-treating-inflammation-and-pain-after-ocular-surgery/2481604/Salvat Laboratories announced the results of phase 3 clinical trials of its ophthalmic corticosteroid at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The studies’ global coordinator, Andrew Schwartz, MD, presented a poster outlinin
- Eyenovia Receives FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasishttps://modernod.com/news/eyenovia-receives-fda-approval-of-mydcombi-the-first-ophthalmic-spray-for-mydriasis/2481603/Eyenovia announced that the FDA has approved Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first approved fixed dose combinatio
- Formosa and AimMax Submit NDA to the FDA for APP13007 for Postoperative Inflammation and Pain After Ocular Surgeryhttps://modernod.com/news/formosa-and-aimmax-announce-the-nda-submission-to-the-fda-for-app13007-for-postoperative-inflammation-and-pain-following-ocular-surgery/2481602/Formosa Pharmaceuticals and AimMax Therapeutics announced the submission of a new drug application to the FDA for APP13007, a novel aqueous nanosuspension formulation of the corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain following ocular surger
- Cassini Launches Cassini Connect Digital Cataract Surgery Suitehttps://modernod.com/news/cassini-launches-cassini-connect-digital-cataract-surgery-suite/2481601/Cassini announced the launch of the Cassini Connect, a digital cataract surgery suite compatible with most leading microscope brands, at the 2023 ASCRS meeting. Cassini Connect offers an integrated cataract surgery workflow and data solution, from pre-op
- Harrow Launches FDA-Approved Iheezo at ASCRShttps://modernod.com/news/harrow-to-launch-fda-approved-iheezo-at-the-2023-ascrs/2481596/Harrow announced the launch of FDA-approved Ihezzo at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting being held May 5‑8, 2023, in San Diego, California. The Harrow commercial team will be available to discuss Iheezo and the entire Harrow